1. Introduction
Pin1, or Protein interacting with Never-in-Mitosis (NIMA) 1, is a phosphorylation-dependent peptidyl-prolyl
cis-trans isomerase (PPIase) [
1]. Unlike the other PPIases, the cyclophilins and FK506 binding proteins, Pin1 is a two-domain protein specific for isomerizing motifs with a proline immediately preceded by a phosphorylated serine or threonine (pS/T-P) [
2]. The N-terminal WW (Trp-Trp) domain binds these motifs, while the C-terminal PPIase domain is responsible for isomerization [
3]. Connecting the two domains is a 10 residue flexible linker (
Figure 1A). Interestingly, the relative positions between the two domains are not fixed, as the two domains can occupy “compact” and “extended” states. In the compact state, the two domains interact through an interdomain (ID) interface between residues 28–32 in the WW domain, and 137–141 and 148–149 in the PPIase (
Figure 1A) [
4,
5]. The position of the domains in the extended state is expected to be a distribution of states, rather than just one [
6,
7,
8]. An equilibrium exists between compact and extended conformations of Pin1 that can be altered by ligands [
9,
10]. Ligand binding and mutation studies suggest that the WW domain allosterically regulates the activity of the PPIase domain.
Figure 1. Structure of Pin1 and ligands. (A) Annotated crystal structure of PDB 1pin. (B) Primary pS/T-P peptide ligands discussed in this review.
Pin1 is a very promiscuous mitotic regulator, and regulates phosphoproteins through changing the phosphorylation/dephosphorylation state, as well as protein stability through either enhancing or protecting against ubiquitin-mediated proteasomal degradation [
11]. Pin1 is overexpressed in many different cancer types, including lung, brain, melanoma, prostate, ovary, and cervical [
12]. In breast cancer, Pin1 has been implicated in RAS/MEK/ERK, WNT/β-catenin, NFκB, HER2, and ERα signaling pathways [
13,
14,
15,
16,
17]. More specifically, Pin1 enhances proteosomal degradation of c-Myc and Cyclin E, while protecting CDK1, β-catenin, NFκB, and p53. Pin1 has even been shown to promote cancer stem cell metastasis and tumorigenesis [
18]. While overexpression of Pin1 is implicated in cancer, Pin1 typically protects against tauopathy and plaque formation that leads to Alzheimer’s disease (AD) neurodegeneration. Pin1 has been shown to regulate both Tau and Aβ, that lead to intracellular tangles and extracellular plaques, respectively [
19,
20,
21,
22]. It is apparent that targeting Pin1 for therapeutics is a substantial challenge, especially due to its opposite roles in AD and cancer.
It is clearly apparent that Pin1 is capable of binding and isomerizing many different substrates, all with the commonality of a pS/T-P motif (
Figure 1). Despite this shared motif, not all substrates cause the same structural changes to Pin1 upon binding. A peptide derivative from the pT48-P49 site of M phase inducer phosphatase Cdc25C with sequence EQPLpTPVTDL (here called pCDC25c) causes Pin1 to favor a hyper-extended state compared to the apo condition [
8]. On the other hand, peptides with sequences WFYpSPR, FFpSPR, and YpSPTpSPS cause a shift to a more compact state of Pin1 [
6]. This ligand-dependent shift in interdomain equilibrium triggers different responses in PPIase dynamics and catalytic activity. The Pintide ligand with sequence WFYpSPR was discovered as the peptide that Pin1 has the highest activity to isomerize [
3], and ligand FFpSPR is similar in sequence but is slightly more hydrophilic and therefore has higher solubility in aqueous buffers. Ligand YpSPTpSPS is based on the repeated sequence in the C-terminal domain of RNA Polymerase II. The primary ligands that have been examined in this review include pCDC25c, FFpSPR, and the CTD of RNA Pol II with peptides drawn in
Figure 1B.
Pin1 has been very extensively studied for the last 20 years, with most structural work aimed at understanding the dynamics and allostery of this two-domain protein. Various studies have been performed looking at Pin1 binding to many different ligands. In this review, we focus specifically on a summary of which mutants in Pin1 impact catalytic activity and ligand binding affinity and to what extent. As such, this review highlights mutations made in biochemical and structural studies. We hope this review aids in computational studies and methodological developments in order to characterize an allosteric system on a per residue basis.
The association of variants with specific diseases is outside the scope of this review. However, the interested reader is referred to an excellent review on single nucleotide polymorphisms and mutations of Pin1 in cancers [
23]. Many other articles exist discussing the role of Pin1 in cancer and Alzheimer’s disease, for example references [
20,
21,
24,
25,
26,
27,
28]. Other reviews describe the role of Pin1 in transcription [
29], the cell cycle and signaling [
30,
31,
32], and its role as a molecular switch in proteasomal degradation [
11]. Lastly, a comprehensive review of the structure and function of Pin1 summarizes the current knowledge in the field [
33].